S&P 500   3,217.49 (+0.62%)
DOW   26,750.47 (+0.40%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,217.49 (+0.62%)
DOW   26,750.47 (+0.40%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,217.49 (+0.62%)
DOW   26,750.47 (+0.40%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,217.49 (+0.62%)
DOW   26,750.47 (+0.40%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NASDAQ:DVAXDynavax Technologies Stock Price, Forecast & News

$9.30
+0.12 (+1.31 %)
(As of 07/15/2020 02:49 PM ET)
Add
Compare
Today's Range
$9.01
Now: $9.31
$9.42
50-Day Range
$4.84
MA: $7.17
$9.42
52-Week Range
$1.80
Now: $9.31
$9.76
Volume3.43 million shs
Average Volume3.93 million shs
Market Capitalization$857.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; and a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Read More
Dynavax Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.22 million
Book Value$0.10 per share

Profitability

Net Income$-152,600,000.00
Net Margins-310.97%

Miscellaneous

Employees231
Market Cap$857.77 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

How has Dynavax Technologies' stock been impacted by COVID-19 (Coronavirus)?

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DVAX stock has increased by 203.1% and is now trading at $9.3050. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dynavax Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dynavax Technologies.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Dynavax Technologies.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $10.92 million during the quarter, compared to analysts' expectations of $10.91 million. Dynavax Technologies had a negative return on equity of 722.75% and a negative net margin of 310.97%. View Dynavax Technologies' earnings history.

What price target have analysts set for DVAX?

4 brokerages have issued 1 year target prices for Dynavax Technologies' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Dynavax Technologies' stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 64.8% from the stock's current price. View analysts' price targets for Dynavax Technologies.

Has Dynavax Technologies been receiving favorable news coverage?

News stories about DVAX stock have trended extremely negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dynavax Technologies earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the near term. View the latest news about Dynavax Technologies.

Who are some of Dynavax Technologies' key competitors?

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Micron Technology (MU), Array Biopharma (ARRY), Gilead Sciences (GILD) and Exelixis (EXEL).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the following people:
  • Mr. Ryan Spencer, CEO & Director (Age 42, Pay $545.59k)
  • Mr. David F. Novack, Pres & COO (Age 58, Pay $697.27k)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 68, Pay $662.54k)
  • Dr. Robert Janssen, Chief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs (Age 66, Pay $666.13k)
  • Mr. David Lee Johnson, VP & Chief Accounting Officer (Age 66)

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include MERIAN GLOBAL INVESTORS UK Ltd (0.02%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David Louis Johnson, Francis Cano, Michael S Ostrach, Robert Coffman and Robert Janssen. View institutional ownership trends for Dynavax Technologies.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano. View insider buying and selling activity for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $9.31.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $857.77 million and generates $35.22 million in revenue each year. The biopharmaceutical company earns $-152,600,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Dynavax Technologies employs 231 workers across the globe.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is www.dynavax.com.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.